Fig. 4

Short-term and long-term hematopoietic engraftment of recipient mice co-infused with purified HSCs and Ad-MSCs. a Donor CD45.1⁺/CD45.2⁺ cell engraftment detected in CD45.2⁺ recipients’ peripheral blood. Five gray-irradiated primary recipients were infused 1500 LSK, with (gray bars) or without (white bars) 6×10⁵ Ad-MSC co-infusion. Secondary and tertiary recipients were irradiated with 11 Gy and transplanted with pooled 2×10⁶ BM cells obtained 24 weeks after HSCT from the primary recipients and at 12 weeks after HSCT from the secondary recipients. b Flow cytometry analysis showing the percentage of LSK cells that were of donor CD45.1⁺/CD45.2⁺ origin in pooled BM samples from primary recipients (CD45.2⁺) 24 weeks after transplantation. c Similar analyses conducted in pooled BM samples from secondary recipients (CD45.2⁺) 12 weeks after transplantation. Bars represent standard error of the mean. *P ≤ 0.05. **P ≤ 0.01. ***P ≤ 0.001. Ad-MSC adipose tissue-derived mesenchymal stem cell, BM bone marrow, HSC hematopoietic stem cell, HSCT hematopoietic stem cell transplant, LSK lineage⁻ Sca-1⁺ cKit⁺, ns non-significant difference